- Conditions
- Kidney Transplant
- Interventions
- IVIG and Rituximab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
- Drug · Procedure · Other
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Renal Disease
- Interventions
- IdeS® (Imlifidase)
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- End Stage Renal Disease
- Interventions
- Rituxan
- Biological
- Lead sponsor
- Stanley Jordan, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
- Interventions
- Clazakizumab
- Drug
- Lead sponsor
- Stanley Jordan, MD
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- End Stage Renal Disease (ESRD)
- Interventions
- Tocilizumab, Intravenous Immunoglobulin
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Kidney Transplantation
- Interventions
- C1 Esterase Inhibitor, Placebos
- Drug
- Lead sponsor
- Stanley Jordan, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Imlifidase
- Drug
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Interventions
- mycophenolate mofetil (CellCept)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Kidney Transplantation in Highly Sensitized Patients
- Interventions
- Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
- Drug · Other
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 9 more
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Vonsetamig
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 7 more
- Conditions
- Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
- Interventions
- Cyclophosphamide, CART-BCMA, huCART19, Fludarabine
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Highly-sensitized Kidney Transplant Recipients
- Interventions
- everolimus + low-dose tacrolimus
- Drug
- Lead sponsor
- Joseph Kahwaji, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Highly Sensitized Patients on Waiting List for Kidney Transplantation
- Interventions
- Inebilizumab, VIB4920, Inebilzumab+VIB4920
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- San Diego, California • Bethlehem, Pennsylvania
- Conditions
- End-Stage Renal Disease, Kidney Transplantation
- Interventions
- Intravenous immune globulin (IVIG)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 1
- States / cities
- Rockville, Maryland